Combination therapy of rosiglitazone, a peroxisome proliferator-activated receptor-γ ligand, and NMDA receptor antagonist (MK-801) on experimental embolic stroke in rats

Basic and Clinical Pharmacology and Toxicology

Volumn 101, Issue 5, 2007, Pages 309-314

  Allahtavakoli, Mohammad ^a   Shabanzadeh, Alireza ^b   Roohbakhsh, Ali ^a   Pourshanazari, Aliasghar ^a  

^a RAFSANJAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

BENZENE DERIVATIVE; DIZOCILPINE; ROSIGLITAZONE; TRIPHENYLTETRAZOLUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ARTIFICIAL EMBOLISM; BLOOD CLOTTING; BRAIN ARTERY; BRAIN INFARCTION; BRAIN INJURY; BRAIN REGION; COMPUTER PROGRAM; CONTROLLED STUDY; EMBOLISM; IMAGING; MALE; MONOTHERAPY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; STAINING; STROKE;

ANIMALS; BEHAVIOR, ANIMAL; BLOOD COAGULATION; BRAIN; CEREBRAL INFARCTION; DIMETHYL SULFOXIDE; DIZOCILPINE MALEATE; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HYPNOTICS AND SEDATIVES; INTRACRANIAL EMBOLISM; NEUROPROTECTIVE AGENTS; PPAR GAMMA; RATS; RECEPTORS, N-METHYL-D-ASPARTATE; STROKE; THIAZOLIDINEDIONES;

RATTUS;

EID: 34848892510     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2007.00127.x     Document Type: Article

References (34)

1. Carmichael ST. Rodent models of focal stroke: size, mechanism, and purpose. NeuroRx 2005 2 : 396 409.
2. Pereira MP, Hurtado O, Cardenas A et al. Rosiglitazone and 15-deoxy-delta(12,14)-prostaglandin J(2) cause potent neuroprotection after experimental stroke through noncompletely overlapping mechanisms. J Cereb Blood Flow Metab 2006 26 : 218 29.
3. Wang CX, Yang T, Shuaib A. An improved version of embolic model of brain ischemic injury in the rat. J Neurosci Methods 2001 109 : 147 51.
4. Lipton SA. Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults. NeuroRx 2004 1 : 101 10.
5. Gerriets T, Stolz E, Walberer M, Kaps M, Bachmann G, Fisher M. Neuroprotective effects of MK-801 in different rat stroke models for permanent middle cerebral artery occlusion. Stroke 2003 34 : 2234 9.
6. Suzuki Y, Takagi Y, Nakamura R, Hashimoto K, Umemura K. Ability of NMDA and non-NMDA receptor antagonists to inhibit cerebral ischemic damage in aged rats. Brain Res 2003 964 : 116 20.
7. Stevenson RW, McPherson RK, Genereux PE, Danbury BH, Kreutter DK. Antidiabetic agent englitazone enhances insulin action in nondiabetic rats without producing hypoglycemia. Metabolism 1991 40 : 1268 74.
8. Fujiwara T, Okuno A, Yoshioka S, Horikoshi H. Suppression of hepatic gluconeogenesis in long-term troglitazone treated diabetic KK and C57BL/KsJ-db/db mice. Metabolism 1995 44 : 486 90.
9. Stumvoll M, Haring HU. Glitazones: clinical effects and molecular mechanisms. Ann Med 2002 34 : 217 24.
10. Yue T, Chen J, Bao W et al. In vivo myocardial protection from ischemia/reperfusin injury by the peroxisome prolifrator-activated receptor-γ agonist reosiglitazone. Circulation 2002 104 : 2588 94.
11. Sundarajan S, Gamboa JL, Victor NA, Wanderi EW, Lust WD, Landreth GE. Peroxisome proliferator-activated receptor-γ ligands reduce inflammation and infarction size in transient focal ischemia. Neuroscience 2005 130 : 685 96.
12. Welch JS, Ricote M, Akiyama TE, Gonzalez FJ, Glass CK. PPARgamma and PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophages. Proc Natl Acad Sci 2003 100 : 6712 7.
13. Culmsee C, Junker V, Kremers W, Thal S, Plesnila N, Krieglstein J. Combination therapy in ischemic stroke: synergistic neuroprotective effects of memantine and clenbuterol. Stroke 2004 35 : 1197 202.
14. Shuaib A, Wang CX, Yang T, Noor R. Effects of nonpeptide V(1) vasopressin receptor antagonist SR-49059 on infarction volume and recovery of function in a focal embolic stroke model. Stroke 2002 33 : 3033 7.
15. Zhang RL, Chopp M, Zhang ZG, Jiang Q, Ewing JR. A rat model of focal embolic cerebral ischemia. Brain Res 1997 766 : 83 92.
16. Asahi M, Huang Z, Thomas S, Yoshimura S, Sumii T, Mori T. Protective effects of statins involving both eNOS and tPA in focal cerebral ischemia. J Cereb Blood Flow Metab 2005 25 : 722 9.
17. Dinapoli VA, Rosen CL, Nagamine T, Crocco T. Selective MCA occlusion: a precise embolic stroke model. J Neurosci Methods 2006 154 : 233 8.
18. Wang CX, Todd KG, Yang Y, Gordon T, Shuaib A. Patency of cerebral microvessels after focal embolic stroke in the rat. J Cereb Blood Flow Metab 2001 21 : 413 21.
19. Bederson JB, Pitts LH, Tsuji M, Nishimura MC, Davis RL, Bartkowski H. Rat middle cerebral artery occlusion evaluation of the model and development of a neurologic examination. Stroke 1986 17 : 472 6.
20. Franowicz JS, Arnsten AF. Actions of alpha-2 noradrenergic agonists on spatial working memory and blood pressure in rhesus monkeys appear to be mediated by the same receptor subtype. Psychopharmacology (Berl) 2002 162 : 304 12.
21. Racine RJ. Modification of seizure activity by electrical stimulation II Motor seizure. Electroencephalogr Clin Neurophysiol 1972 32 : 281 94.
22. Chakrabarti R, Vikramadithyan RK, Kumar MP, Kumar SK, Mamidi NV, Misra P. PMT13 a pyrimidone analogue of thiazolidinedione improves insulin resistance-associated disorders in animal models of type 2 diabetes. Diabetes Obes Metab 2002 4 : 319 28.
23. Allahtavakoli M, Shabanzadeh AP, Sadr SS, Parviz M, Djahanguiri B. Rosiglitazone a peroxisome proliferator-activated receptor-γ ligand reduces infarction volume and nurological deficits in an embolic model of stroke. Clin Exp Pharmacol Physiol 2006 33 : 1052 8.
24. Begon S, Pickering G, Eschalier A, Dubray C. Magnesium and MK-801 have a similar effect in two experimental models of neuropathic pain. Brain Res 2000 887 : 436 9.
25. Church J, Zeman S, Lodge D. The neuroprotective action of ketamine and MK-801 after transient cerebral ischemia in rats. Anesthesiology 1988 69 : 702 9.
26. Lyden PD, Jackson-Friedman C, Shin C, Hassid S. Synergistic combinatorial stroke therapy: a quantal bioassay of a GABA agonist and a glutamate antagonist. Exp Neurol 2000 163 : 477 89.
27. Lee J, Reding M. Effect of thiazolidinediones on stroke recovery: a case-matched cntrolled study. Neurochem Res 2007 32 : 635 8.
28. Bordet R, Ouk T, Petrault O et al. PPAR a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases. Biochem Soc Trans 2006 34 : 1341 6.
29. Sundarajan S, Landreth GE. Antiinflammatory properties of PPARγ agonists following ischemia. Drug News Perspect 2004 17 : 229 35.
30. Aoun P, Watson DG, Simpkins JW. Neuroprotective effects of PPARgamma agonists against oxidative insults in HT-22 cells. Eur J Pharmacol 2003 472 : 65 71.
31. Heneka MT, Klockgether T, Feinstein DL. Peroxisome proliferator-activated receptor-gamma ligands reduce neuronal inducible nitric oxide synthase expression and cell death in vivo. J Neurosci 2000 20 : 6862 7.
32. Uryu S, Harada J, Hisamoto M, Oda T. Troglitazone inhibits both post-glutamate neurotoxicity and low-potassium-induced apoptosis in cerebral granule neurons. Brain Res 2002 924 : 229 36.
33. Barth AL, Newell DW. Combination therapy with MK-801 and a-phenyl-tert-butyl-nitrone enhances protection against ischemic neuronal damage in organotypic hippocampal slice cultures. Exp Neurol 1998 141 : 330 6.
34. Parker JC. Troglitazone, the discovery and development of a novel therapy for the treatment of Type 2 diabetes mellitus. Adv Drug Deliv Rev 2002 54 : 1173 97.